Compare SBUX & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SBUX | SNY |
|---|---|---|
| Founded | 1971 | 1994 |
| Country | United States | France |
| Employees | N/A | 74846 |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 105.7B | 116.8B |
| IPO Year | 1994 | N/A |
| Metric | SBUX | SNY |
|---|---|---|
| Price | $101.47 | $43.97 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 26 | 6 |
| Target Price | ★ $100.84 | $61.50 |
| AVG Volume (30 Days) | ★ 6.7M | 4.1M |
| Earning Date | 04-29-2026 | 01-01-0001 |
| Dividend Yield | 2.44% | ★ 3.64% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.26 | N/A |
| Revenue | ★ $37,184,400,000.00 | N/A |
| Revenue This Year | $5.26 | $3.01 |
| Revenue Next Year | $5.47 | $5.80 |
| P/E Ratio | $389.90 | ★ $6.14 |
| Revenue Growth | ★ 2.79 | N/A |
| 52 Week Low | $75.50 | $43.51 |
| 52 Week High | $104.82 | $59.17 |
| Indicator | SBUX | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 65.23 | 32.70 |
| Support Level | $82.38 | N/A |
| Resistance Level | $104.82 | $48.97 |
| Average True Range (ATR) | 2.48 | 0.68 |
| MACD | 0.22 | -0.38 |
| Stochastic Oscillator | 95.91 | 8.21 |
Starbucks stands out as the world's biggest and most recognizable coffee brand, powered by ultracustomizable beverages in-store and a sweeping footprint of nearly 41,000 cafes in over 80 countries. About 52% are company-operated, with the balance run by licensees. The company operates roasteries and sells across its North America (74% of revenue as of the end of fiscal 2025), international (21%), and channel development (5%) segments. The brand collects revenue from company-operated stores, licensee royalties, equipment and product sales, retail ready-to-drink beverages, and packaged coffee.
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.